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introDuCtion
Prostate cancer in European males has a high incidence, 
with nearly 450,000 cases diagnosed per year.1 In low–
intermediate risk prostate disease external beam radio-
therapy is a well- established treatment either alone, 
or in combination with androgen deprivation therapy. 
Other treatment options include active surveillance, 
brachytherapy and surgery. Treatment choice depends 
on stage and associated toxicity.2–4 Stereotactic ablative 
radiotherapy (SABR) delivers high doses of precise radio-
therapy, over a short course.5 The low α/β ratio of pros-
tate cancer, compared with surrounding normal tissue 
supports the rationale for SABR.6 A shorter treatment 
course being an attractive option for patients due to less 
department visits.
A meta- analysis of over 6000 low–intermediate risk pros-
tate cancer patients treated with SABR in 5–10 Gy over 4–9 
fractions, shows acceptable toxicity and patient reported 
quality of life.7 Prostate SABR requires randomised 
controlled data to support it as standard of care, long- term 
effects still under review. Early reports of prostate advances 
in comparative evidence (PACE) study are encouraging, 
although recent reports from HYPO- RT- PC trial suggests 
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objective: Prostate stereotactic ablative radiotherapy 
(SABR) delivers large doses using a fast dose rate. This 
amplifies the effect geometric uncertainties have on 
normal tissue dose. The aim of this study was to deter-
mine whether the treatment dose–volume histogram 
(DVH) agrees with the planned dose to organs at risk 
(OAR).
Methods: 41 low–intermediate risk prostate cancer 
patients were treated with SABR using a linac based 
technique. Dose prescribed was 35 Gy in five fractions 
delivered on alternate days, planned using volumetric 
modulated arc therapy (VMAT) with 10X flattening filter 
free (FFF). On treatment, prostate was matched to 
fiducial markers on cone beam CT (CBCT). OAR were 
retrospectively delineated on 205 pre- treatment CBCT 
images. Daily CBCT contours were overlaid on the plan-
ning CT for dosimetric analysis. Verification plan used 
to evaluate the daily DVH for each structure. The daily 
doses received by OAR were recorded using the D%.
results: The median rectum and bladder volumes at 
planning were 67.1 cm3 (interquartile range 56.4–78.2) 
and 164.4 cm3 (interquartile range 120.3–213.4) respec-
tively. There was no statistically significant difference in 
median rectal volume at each of the five treatment scans 
compared to the planning scan (p = 0.99). This was also 
the case for median bladder volume (p = 0.79). The 
median dose received by rectum and bladder at each 
fraction was higher than planned, at the majority of dose 
levels. For rectum the increase ranged from 0.78–1.64Gy 
and for bladder 0.14–1.07Gy. The percentage of patients 
failing for rectum D35% < 18 Gy (p = 0.016), D10% < 28 Gy 
(p = 0.004), D5% < 32 Gy (p = 0.0001), D1% < 35 Gy (p 
= 0.0001) and bladder D1% < 35 Gy (p = 0.001) at treat-
ment were all statistically significant.
Conclusion: In this cohort of prostate SABR patients, 
we estimate the OAR treatment DVH was higher than 
planned. This was due to rectal and bladder organ 
variation.
advances in knowledge: OAR variation in prostate 
SABR using a FFF technique, may cause the treatment 
DVH to be higher than planned.
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Advanced radiotherapy planning improves dose to the target 
volume, and minimises normal tissue dose by sculpting dose 
distributions. In addition, image- guided radiotherapy (IGRT) 
allows accurate and precise daily prostate positioning.10,11 
Current technology allows the delivery of SABR on a linear 
accelerator using flattening filter free (FFF) mode in around 
2 min per fraction. We previously published our linac- based 
SABR safety and feasibility study results, showing clinically 
acceptable toxicity in 41 patients.12 In a series of 90 patients the 
D’Agostino (2016) group in Milan, also report mild toxicity and 
observe minimal effect on quality of life up to 2 years using a 
similar FFF technique.13
A SABR technique improves the conformity; nonetheless there 
are many challenges to overcome, e.g. the prostate sits adjacent 
to organs at risk (OAR), the rectum and bladder. These organs 
are mobile and deform depending on patient physiology, often 
causing overlap of volumes. As the treatment planning system 
calculates the radiotherapy treatment plan based on planning CT 
anatomy, subsequent variations are not accounted for.
Dose–volume histogram (DVH) data are derived from CT, which 
forecasts treatment dose, meaning effects of daily organ changes 
may be ignored.14–17 For this reason, DVH being representative 
of the delivered plan is central to the success of an advanced 
planning technique.18 Organ motion can result in setup error 
and geometric uncertainty, which may negatively impact target 
coverage and normal tissue dose.14 There is limited evidence on 
the optimal planning dose constraints using a linear accelerator 
FFF technique, with recent consensus based on trials.19
In SABR, the need to reproduce and deliver the desired plan is 
pertinent. Any deviation could result in a geographical miss or 
undesirable normal tissue dose.20 FFF delivery mode allows a 
faster dose delivery rate, where organ deviations and uncertain-
ties may have more effect. Delivery of a large dose per fraction 
could amplify this further. As the number of fractions decrease, 
organ changes may impact more.6,10,21,22 In these circumstances 
where the goal to enhance the therapeutic ratio with accuracy, 
precision, and improved conformity could be lost.23
We aimed to determine whether the treatment DVH agrees with 
the planned dose to OAR. Objectives for this study were to:
(1) Quantify variation in organ volume.
(2) Determine if on treatment rectum and bladder DVH exceeds 
the planned DVH.




This was a retrospective planning sub study of patients treated 
with prostate SABR in PRO SABR study (A pilot study to assess 
acute gastrointestinal and genitourinary toxicity in patients 
treated with FFF SABR for prostate cancer) (n = 41), ethically 
approved by the West of Scotland Ethics Committee on 25th 
April 2013 (13/WS/0091). The dose prescribed was 35 Gy in 
5 fractions, delivered over alternate days using a volumetric 
modulated arc therapy (VMAT) 10x FFF technique (RapidarcTM, 
Varian Medical Systems, Palo Alto, CA) as previously described.12
Treatment planning
Delineation was performed on a registered MRI/CT image set. 
The clinical target volume (CTV) was the prostate only (or in 
some circumstances prostate plus seminal vesicles) as outlined 
by the clinical oncologist. The planning target volume (PTV) was 
taken as CTV with 5 mm margins added in all directions except 
posteriorly, where 3 mm was used to minimise rectum dose. The 
OAR, were the rectum (from the anus to the rectosigmoid junc-
tion), the bladder (including wall and lumen) and left and right 
femoral heads.
Treatment and verification
For both planning and treatment delivery, patients were 
instructed to use a microlax enema preparation, empty their 
bladder and drink 450 ml of water 30 min before scanning. Treat-
ment was delivered on a Varian Truebeam STx linear accelerator 
(Varian Medical Systems, Palo Alto, CA). Immediately before 
each treatment following preparation and setup, participants 
had a pre- treatment cone- beam CT (CBCT) scan. Acquired 
using "Pelvis" acquisition mode, the half- fan bowtie filter, with 
settings of 1080mAs 125kV, 80mA. Daily CBCT images (#1–5) 
were registered with the planning CT (CTp) based on fiducials. 
Any mismatch was corrected by applying all shifts. PTV coverage 
and OAR position was approved online by a clinical oncologist.
CBCT contouring and plan evaluation
The CBCT image set was registered with the CTp at the online seed 
match treatment position. The rectum and bladder were manu-
ally contoured on CTp and each CBCT (#1–5) by one observer 
to ensure consistency, peer reviewed by a second observer. CBCT 
contours were transferred to the CTp structure set. A verifica-
tion plan was created using Eclipse V10.0.39 (Varian Medical 
Systems, Palo Alto, CA) and calculated for 1 fraction of 700cGy 
on the CTp data set. Verification plans were re- calculated using 
anisotropic analytical algorithm (AAA 10.0.28) on a calculation 
grid of 1.25 mm.
Data analysis
The initial planning constraints for OAR were rectum, V18Gy 
< 35%, V28Gy < 10%, V32Gy < 5%, V35Gy < 1% and bladder 
V35Gy < 1%.
Dose received to the rectum and bladder was evaluated on the 
DVH at each individual fraction. To evaluate the dose received 
by each organ at an individual fraction, the dose to the constraint 
% volume of the structure was measured, and dose received at 
this volume recorded. The dose measured at each fraction at the 
specified % volume was added together to estimate the delivered 
DVH. This was then compared to the dose at the structure ratio 
(D%) of the planning DVH.
Statistical tests
DVH were exported from Eclipse V10.0.39 (Varian Medical 
Systems, Palo Alto, CA) and imported into StataCorp Stata 
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Statistical Software: v. 14.0 for analysis. Statistical significance 
was set at a level of 5%, and all tests used were two- sided. The 
Wilcoxon sign rank test of equality was used to determine if 
there were differences between the structure volumes at planning 
and treatment. McNemars test of proportions in matched pairs 
was used to determine if there were differences in the propor-
tion of patients failing to meet specific constraints at treatment in 
comparison to planning. Spearman rank correlation coefficients 
were used to describe the associations between dose and organ 
volume.
results
All 41 patients recruited to the PRO SABR study between 
November 2013 to June 2016 were included for analysis. The 
median age was 68 years [interquartile range (IQR) 65–71]. 
Patient characteristics are reported in Table 1. A total of 205 pre- 
treatment CBCT scans were dosimetrically analysed.
Planning statistics
The median CTV and PTV volumes were 36.0 cm3 (IQR 29.9–
45.1) and 76.4 cm3 (IQR 64.8–90.1) respectively. All plans 
achieved the objective that 99% of the CTV should receive at 
least 95% dose, and that 95% of the PTV should receive at least 
95% prescribed dose.
Volume of rectum and bladder
Figure  1 shows the variation in bladder and rectum volume 
over the planning and five treatment fractions for patient 23. 
For all patients, the median rectum and bladder volumes at 
planning were 67.1 (IQR 56.4–78.2) and 164.4 (IQR 120.3–
213.4) cm3 respectively. Overall, there was no statistically 
significant difference in median rectal volume at each of the five 
pre- treatment scans compared to the planning scan (p = 0.99 
(Table 2)). This was also the case for median bladder volume 
(p = 0.79). The median difference in volumes for the rectum 
ranged from −3 (at fraction 2) to 2.4 cm3 (fraction 4). For the 
bladder volume, the difference ranged from −10.6 (fraction 3) 
to 17.6 cm3 (fraction 5). In contrast, the percentage of the OAR 
overlapping the planning PTV increased at treatment. For the 
rectum, the median overlap at planning was 2.3% and this 
increased to 5.3% at the first treatment (p < 0.0001). Similarly, 
the median percentage of the bladder overlapping the plan-
ning PTV increased from 2.6% at planning to 3.9% at treat-
ment (p < 0.0001).
Figure  2 shows the rectal and bladder volume from each pre- 
treatment scan plotted against the respective planning volume. 
The figure shows substantial regression to the mean, where there 
is more systematic change at the tails of the planning measure-
ments; patients with small volumes at planning have larger 
volumes at treatment, and patients with large volumes at plan-
ning had lower volumes at treatment. The intrapatient correla-
tion coefficient for rectum volume was 0.60 [95% CI 0.47–0.72) 
which was stronger than that found for bladder 0.45 (95% CI 
0.32–0.60). The intra patient correlation coefficient indicates 
the degree to which volume measures are stable over fractions. 
Relative to the planning volume, 68% of the variation in bladder 
volume and 42% of variation in rectum volume was attributed to 
variation within patients.
Table 1. Patient characteristics
Baseline characteristics (n = 41)
Median (IQR) 
or % (n)
Age (years) 68 (65–71)
Initial PSA (ng/ml) 10.5 (8.0–13.3)
T stagea 1 14.6 (6)
2 82.9 (34)
Gleason score 6 41.5 (17)
7 58.5 (24)
Androgen deprivation therapy No 24.4 (10)
Yes 75.6 (31)
IQR, interquartile range; PSA, prostate- specific antigen.
aT- stage not recorded for one patient
Figure 1. Superimposed rectal and bladder contours from planning CT (black contour) and each fraction (white contour) for 
patient 23 on axial and sagittal view of original planning scan.
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Dose to ratio of percentage of structure rectum 
and bladder
Table 3 shows the dose received by each percentage of volume on 
treatment and the planned dose. For both rectum and bladder, 
with four exceptions, the median dose received at each fraction 
was higher than that expected at planning. Figure 3 shows the 
difference in delivered dose and the planned dose. For each % of 
rectum the median difference between dose delivered and dose 
planned range from 0.78 to 1.64 Gy, for the bladder the increase 
was smaller and ranged from 0.14 to 1.07 Gy. The figure shows 
that an increase of up to 5 Gy occurred for some patients.
Dose constraints
Table 4 shows the dose constraints and the number of patients 
who failed at planning and at treatment. At planning, two 
patients [4.9%, 95% CI (0.6–15.5%)] failed to meet the constraint 
that the dose to 35% of the rectum (D35%) should be less than 
18 Gy. At treatment, the number increased to 9 (22.0%, 95% CI 
(10.6–37.6%)), p = 0.016). The percentage failing each of the 
other constraints D10% < 28 Gy, D5% < 32 Gy and D1% < 35 Gy 
similarly showed a statistically significant increase at treatment 
compared to that expected at planning. For the dose delivered to 
the bladder, at planning four patients (9.8%) failed the constraint 
that the dose received by 1% of the bladder (D1%) should be less 
than 35 Gy. This increased to 18 patients (43.9%, 95% CI (28.5–
60.3%)) at treatment (p = 0.001).
Table 5 presents the correlation between dose and volume when 
they are both expressed relative to the values expected at plan-
ning. The table shows that for 1% of the rectum the correlation 
was positive (p = < 0.001). This means that when the volume of 
1% of the rectum was greater than that expected at planning the 
dose received by 1% was higher than what had been planned. For 
D5% and D10% there was no statistically significant association, 
and for D35% the correlation was negative (p =< 0.001) so that 
as the volume of 35% of the rectum increased relative to what 
had been documented at planning the dose received by 35% of 
the organ decreased. The correlation between relative dose and 
relative volume for the bladder at D1% was negative.
DisCussion
In this cohort of prostate cancer patients treated with SABR, we 
aimed to determine whether the treatment DVH agrees with 
the planned dose to OAR. Our results indicate the OAR treat-
ment DVH was higher than planned. The volume of OAR shows 
inter fraction variation with significant regression to the mean, 
but we did not observe systematic variation during treatment. 
While analysis of planned DVH indicates treatment constraints 
would be met by most patients, on treatment DVH estimates that 
over 40% of patients fail these constraints. To our knowledge we 
are the first to report OAR variation in SABR using a linac based 
FFF technique.
Our findings are difficult to compare to the literature, where 
studies in conventional prostate radiotherapy describe varying 
methods to assess delivered dose with only two studies identified 
in the SABR setting.15,18,24–32
Evidence of volume changes is lacking in SABR with inter frac-
tion rectal variation well documented in conventional radio-
therapy.17,25,26,33,34 We found no systematic change for rectal 
volume, although Maund et al. (2014) report rectal volume 
decreases on treatment. This study was without bowel prepara-
tion, only offering patients dietary advice.33 Patients in our study 
were given a micro enema prior to planning and each fraction. 
Visual assessment led us to observe rectum filing was often to 
be at the superior aspect, near to the recto sigmoid junction, in 
agreement with previous authors.35 Our study lacks analysis of 
change for any particular portion of the rectum; this could be an 
aspect for future work.
Table 2. Rectum and bladder volume at planning and each fraction with PTV overlap
Volume (cm3) Volume overlap with PTV (%)
Organ
Planning or treatment 
fraction number Median IQR Median IQR
Rectum Planning 67.1 (56.4–78.2) 2.3 (1.0–3.4)
1 65.7 (56.3–83.1) 5.3 (2.7–7.2)
2 67.1 (56.3–81.2) 4.2 (1.7–7.9)
3 66.3 (58.2–83.6) 4.1 (1.1–5.9)
4 71.3 (58.8–78.3) 4.2 (1.6–6.1)
5 66.6 (58.3–79.4) 5.0 (1.9–7.4)
Bladder Planning 164.4 (120.3–213.4) 2.6 (1.6–5.9)
1 146.8 (115.8–196.8) 3.9 (2.6–7.9)
2 173.7 (119.6–231.2) 3.5 (1.8–6.2)
3 162.4 (128.4–246.5) 3.1 (1.3–8.0)
4 156.4 (114.0–247.4) 2.7 (1.6–7.2)
5 147.9 (117.2–202.5) 3.7 (2.1–6.6)
IQR, interquartile range; PTV, planning target volume.
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Bladder volume when we compare to rectal volume, shows larger 
inter fraction variation for all patients, agreeing with previous 
work in conventional regimes.18,25,29,30,36 Our study found no 
statistically significant change in bladder volume from planning 
to treatment, as did others.29 We found at least 20 patients on at 
least one occasion, had a bladder volume which was 50% greater 
than that at planning, and 9 patients with a bladder volume less 
than 50% of that at planning. Variations as large as 58% have 
previously been reported.25,29
Our analysis of bladder and rectal volumes suggests substantial 
regression to the mean indicating there may be an optimum 
planning volume which could potentially predict patients where 
change on treatment is most likely.
Figure 2. Scatter plot of individual patients’ rectum and bladder volumes at planning and each treatment.
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In the SABR setting there have been attempts to analyse deliv-
ered dose to OAR. In one analysis, real time monitored trans-
lations calculated on the CTp account for intra fraction motion, 
but negate daily organ variations.32 Similarly Wahl et al. (2017) 
use methods that predict organ variation based on conventional 
radiotherapy images. The authors apply these organ changes to 
the SABR plan, without recognition of the daily organ variation. 
Our results show volume changes could be significant over the 
course of five fractions in an SABR plan.24
Our findings show large variation in delivered dose to the 
rectum, consistent with previously published results in SABR 
and conventional radiotherapy.15,18,24,27,28,36 We found a positive 
association, between overall rectal volume and estimate of dose 
received by 1% of rectum volume; and a negative association with 
estimate of dose received by 35% of rectum volume. Looking at 
the dose received by 5 and 10% rectal volume and overall rectal 
volume, we found no statistically significant association.
Our analysis estimates a significant increase in delivered dose to 
the bladder, previous work supports this difference.15,28,31,36–38 
However, this could be attributed to the bladder only having 
one planning constraint set at V35Gy < 1%. Others report no 
significant difference between planned and delivered dose.24,29 
The correlation we observe between dose to 1% of the bladder 
and the volume was negative (p = 0.004). The bladder volume 
increase is associated with a decrease in dose which previous 
studies observe.24,26,29
Our study used dose volume analysis to estimate the delivered 
dose to OAR as have other researchers.15,18,24–27,29,34,37 This meth-
odology lacks spatial information as it provides two- dimensional 
data and negates three- dimensional volumetric information.
A variety of approaches have been undertaken to add spatial 
information. The summation of DVH’s in a vector based method 
which minimises effects of overlying dose distributions, deform-
able image registration (DIR), and using commercially available 
programs to develop dose accumulation on a voxel by voxel 
basis.31,36,39–42 Others adopt multivariate analysis in the form of 
models to predict dose.30
Most methodologies have recognised issues. In a deforming 
organ, some suggest fraction dose cannot be added, offering DIR 
as a solution.36 Studies have used DIR to add spatial information 
to DVH analysis.36,38,42 However, DIR may be unreliable in the 
pelvis due to the nature of organ changes, with arguments that 
deforming dose to assess accumulation should not be used clin-
ically.43–46 Deformable dose accumulation techniques produce 
one resultant dose distribution, which may be a limitation.42 
Interestingly, in a study using DVH analysis and DIR, Andersen 
et al. conclude that adding DVHs is a good indicator of bladder 
delivered dose.38 They assessed and compare using a DIR method 
which did little to further evaluate delivered dose.
Commercially available DIR algorithms have improved recently, 
with each algorithm handling clinical case specific scenarios 
differently. Quality assurance of each algorithm is essential for 
safe clinical interpretation to aid an adaptive workflow.47 Chal-
lenges, specifically in the pelvic region where tissues that are 
"sliding tissues," e.g. bladder and rectum can cause suboptimal 
registrations.48,49
A limitation of our study is that CBCT images were acquired 
pre- treatment and our data lack intrafraction motion, previous 
work discusses this.18 The findings we report here could there-
fore be greater, as they assume a perfect fiducial marker match 
Table 3. Dose received by each percentage of volume at planning and treatment
Percentage of organ volume

















Rectum Planning 6.76 (6.68–6.88) 6.11 (5.85–6.29) 5.22 (4.92–5.43) 2.92 (2.46–3.37)
1 7.00 (6.85–7.12) 6.52 (6.18–6.76) 5.63 (5.23–6.12) 3.20 (2.85–3.47)
2 6.96 (6.81–7.07) 6.50 (5.90–6.78) 5.66 (4.96–6.20) 3.29 (2.72–3.56)
3 6.98 (6.71–7.07) 6.44 (5.82–6.67) 5.61 (5.05–6.00) 3.17 (2.84–3.55)
4 6.98 (6.77–7.08) 6.31 (5.98–6.68) 5.45 (4.91–5.97) 3.22 (2.76–3.40)
5 6.98 (6.75–7.14) 6.40 (6.06–6.76) 5.63 (5.21–6.15) 3.32 (2.83–3.74)
Bladder Planning 6.83 (6.68–6.89) 5.76 (5.16–6.64) 4.42 (3.72–5.76) 1.08 (0.59–2.38)
1 7.05 (6.83–7.16) 6.45 (5.58–6.88) 4.97 (3.94–6.27) 1.65 (0.60–2.63)
2 7.03 (6.73–7.15) 6.15 (5.10–6.78) 4.21 (3.54–5.64) 1.47 (0.50–2.35)
3 6.97 (6.72–7.11) 5.95 (4.80–6.85) 4.20 (3.58–5.91) 1.00 (0.71–2.25)
4 6.84 (6.70–7.12) 5.82 (5.13–6.88) 4.31 (3.52–6.24) 1.22 (0.60–2.53)
5 6.99 (6.78–7.15) 6.26 (5.49–6.81) 4.54 (3.70–5.85) 1.60 (0.62–2.52)
IQR, interquartile range.
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throughout treatment. In the SABR setting this a concern where 
margins are tighter and dose gradients steeper than conventional 
techniques.
In a planning study, MacDougall et al suggest intrafraction motion 
can be mitigated with a strict rectal and bladder protocol.50 
However, we observed large volume variations in this patient popu-
lation, even with a robust patient preparation protocol. This implies 
intrafraction motion could be more of an issue in SABR than this 
paper details. Our findings lead us to question how effective our 
local bowel and bladder preparation is, although it is unclear how 
we could improve this, with lack of consensus in the literature.35
Figure 3. The difference in cumulative and planned dose to rectum and bladder at specified volumes.
8 of 10 birpublications.org/bjr Br J Radiol;93:20190789
BJR  Devlin et al
Online plan adaption is a solution to mitigate daily prostate 
deformation and organ changes. Future developments of the 
MR linac are exciting, enabling real- time planning in a timely 
manner, accounting for intra- and interfraction errors.51 Poten-
tially hypofractionated regimes could benefit most from these 
new adaptive strategies, given the capability of delivering daily 
optimised plans, ensuring normal tissue dose is minimised.
A strength of our study is that this is a homogenous group of 
patients, who were part of a clinical trial planning protocol and 
dose constraints. Our results, based on daily imaging informa-
tion, give full treatment course information.
ConClusion
In this cohort of prostate cancer patients, treated with linac- 
based SABR, we estimate the OAR treatment DVH was higher 
than anticipated at planning. Our findings estimate the deliv-
ered dose to rectum and bladder to be higher at the majority of 
dose levels. We have demonstrated safety and feasibility in this 
group of patients, however the interfraction organ variations we 
observe here may be a cause for concern.12 To our knowledge, 
this is the first study to report interfraction organ variation in a 
series of prostate SABR patients using daily CBCT images and 
DVH analysis. Further work in the SABR setting is required to 
investigate delivered dose to normal tissue.
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Table 4. Dose (Gy) to ratio (D%) of rectum and bladder structures at planning and treatment
Planning Treatment
Dose to ratio of 
structure
Patients failing 
constraint % 95% CI
Patients failing 
constraint % 95% CI
Rectum       
D35% < 18 Gy 2 4.9 (0.6–15.5) 9 22.0 (10.6–37.6) p = 0.016
D10% < 28 Gy 7 17.1 (7.1–32.1) 19 46.3 (30.7–62.6) p = 0.004
D5% < 32 Gy 4 9.8 (2.7–23.1) 19 46.3 (30.7–62.6) p = 0.0001
D1% < 35 Gy 2 4.9 (0.6–15.5) 17 41.5 (26.3–57.9) p = 0.0001
Bladder       
D1% < 35 Gy 4 9.8 (2.7–23.1) 18 43.9 (28.5–60.3) p = 0.0001
CI, confidence interval.
p- values based on McNemars test of proportions in matched pairs.





  1 0.364 p < 0.0001
  5 0.088 p = 0.21
  10 −0.087 p = 0.22
  35 −0.460 p < 0.0001
Bladder volume (%)
  1 −0.245 p = 0.0004
Correlation shows if there is association between relative dose 
(relative to planning) and relative volume (relative to planning 
volume).
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